{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,17]],"date-time":"2026-05-17T13:07:08Z","timestamp":1779023228987,"version":"3.51.4"},"reference-count":28,"publisher":"SAGE Publications","license":[{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"funder":[{"DOI":"10.13039\/100010877","name":"ViiV Healthcare","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100010877","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["J Int Assoc Provid AIDS Care"],"published-print":{"date-parts":[[2026,1]]},"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>GLACIER (Giving Long-Acting Cabotegravir plus rilpivirine [CAB\u2009+\u2009RPV LA] in an Infusion Center [IC]) is a Phase 4 implementation study evaluating the perspective of people living with HIV-1 (participants) and IC staff on CAB\u2009+\u2009RPV LA delivery at ICs over 8 months.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Participants and IC staff completed quantitative questionnaires on feasibility (Feasibility of Intervention Measure [FIM]) and acceptability (Acceptability of Intervention Measure [AIM]) at Month (M) 1, M3, and M8; both scales comprised four items, rated on a 1 to 5 Likert scale (1 \u201ccompletely disagree\u201d to 5 \u201ccompletely agree\u201d). Semistructured qualitative interviews and clinical outcomes data were also collected.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Among 44 enrolled participants (mean age 46 years), 51% were CAB\u2009+\u2009RPV LA-naive; 113 IC staff were enrolled. At M1, mean FIM scores (standard deviation [SD]) indicated that both groups found IC administration highly feasible (participants: 4.44 [0.80]; IC staff: 3.71 [0.97]), with scores remaining high at M3 (participants: 4.53 [0.69]; IC staff: 3.86 [0.72]) through to M8 (participants: 4.41 [0.80]; IC staff: 4.00 [0.81]). Similar findings were observed for mean AIM scores (SD), indicating high acceptance at M1 (participants: 4.51 [0.66]; IC staff: 3.65 [0.89]) to M3 (participants: 4.60 [0.67]; IC staff: 3.60 [0.97]) through to M8 (participants: 4.51 [0.55]; IC staff: 3.96 [0.84]). Qualitative data supported these observations. Of 194 injections, 96.4% were within the treatment window; virological suppression was maintained with no confirmed virological failures or adverse event-related discontinuations.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>CAB\u2009+\u2009RPV LA administration at ICs was feasible, acceptable, well-tolerated, and effective.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>ClinicalTrials.gov number<\/jats:title>\n                    <jats:p>\n                      NCT04982445 (\n                      <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"https:\/\/clinicaltrials.gov\/study\/NCT04982445\">https:\/\/clinicaltrials.gov\/study\/NCT04982445<\/jats:ext-link>\n                      )\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1177\/23259582261439585","type":"journal-article","created":{"date-parts":[[2026,5,12]],"date-time":"2026-05-12T12:25:08Z","timestamp":1778588708000},"update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":0,"title":["Feasibility, Fidelity, and Effectiveness of Administering Long-Acting Cabotegravir + Rilpivirine in Infusion Centers in the United States: Findings From the Phase 4 GLACIER Implementation Study"],"prefix":"10.1177","volume":"25","author":[{"given":"Cassidy A.","family":"Gutner","sequence":"first","affiliation":[{"name":"ViiV Healthcare"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Conn","family":"Harrington","sequence":"additional","affiliation":[{"name":"ViiV Healthcare"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gilda","family":"Bontempo","sequence":"additional","affiliation":[{"name":"ViiV Healthcare"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sivakumar","family":"Pazhamalai","sequence":"additional","affiliation":[{"name":"GSK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Abhishek","family":"Kumar","sequence":"additional","affiliation":[{"name":"GSK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kelly","family":"Rimler","sequence":"additional","affiliation":[{"name":"GSK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Karen","family":"Davis","sequence":"additional","affiliation":[{"name":"ViiV Healthcare"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Will","family":"Williams","sequence":"additional","affiliation":[{"name":"GSK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Deanna","family":"Merrill","sequence":"additional","affiliation":[{"name":"ViiV Healthcare"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lisa","family":"Petty","sequence":"additional","affiliation":[{"name":"ViiV Healthcare"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cindy","family":"Garris","sequence":"additional","affiliation":[{"name":"ViiV Healthcare"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Supriya","family":"Sarkar","sequence":"additional","affiliation":[{"name":"ViiV Healthcare"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Patrick","family":"Daniele","sequence":"additional","affiliation":[{"name":"a business unit of Thermo Fisher Scientific"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bridget","family":"Gaglio","sequence":"additional","affiliation":[{"name":"a business unit of Thermo Fisher Scientific"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Katie","family":"May","sequence":"additional","affiliation":[{"name":"Infusion Associates"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael","family":"Aboud","sequence":"additional","affiliation":[{"name":"ViiV Healthcare"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maggie","family":"Czarnogorski","sequence":"additional","affiliation":[{"name":"ViiV Healthcare"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"179","published-online":{"date-parts":[[2026,5,12]]},"reference":[{"key":"e_1_3_3_2_2","unstructured":"European AIDS Clinical Society (EACS). EACS Guidelines Version 12.1 November 2024. 2024. Available at: https:\/\/eacs.sanfordguide.com. [Accessed July 30 2025]."},{"key":"e_1_3_3_3_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2024.2985"},{"key":"e_1_3_3_4_2","unstructured":"Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the Use of Antiretroviral Agents in Adults and Adolescents with HIV. Department of Health and Human Services. 2024. Available at: https:\/\/clinicalinfo.hiv.gov\/sites\/default\/files\/guidelines\/documents\/adult-adolescent-arv\/guidelines-adult-adolescent-arv.pdf. [Accessed July 30 2025]."},{"key":"e_1_3_3_5_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(24)00289-5"},{"key":"e_1_3_3_6_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1909512"},{"key":"e_1_3_3_7_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(20)32666-0"},{"key":"e_1_3_3_8_2","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3018(23)00136-4"},{"key":"e_1_3_3_9_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1904398"},{"key":"e_1_3_3_10_2","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofaf220"},{"key":"e_1_3_3_11_2","doi-asserted-by":"publisher","DOI":"10.1007\/s40121-023-00890-2"},{"key":"e_1_3_3_12_2","doi-asserted-by":"publisher","DOI":"10.1002\/jia2.26003"},{"key":"e_1_3_3_13_2","doi-asserted-by":"publisher","DOI":"10.1002\/jia2.26243"},{"key":"e_1_3_3_14_2","doi-asserted-by":"publisher","DOI":"10.1177\/23259582241269837"},{"key":"e_1_3_3_15_2","volume-title":"Navigating a New Model of HIV Treatment Delivery: Development and Optimization of a Blueprint for Implementation of CABENUVA in Infusion CentersInternational Conference on HIV Treatment and Prevention Adherence (IAPAC)","author":"Gutner C","unstructured":"Gutner C, Haley A, Merrill D, et al. Navigating a New Model of HIV Treatment Delivery: Development and Optimization of a Blueprint for Implementation of CABENUVA in Infusion Centers. International Conference on HIV Treatment and Prevention Adherence (IAPAC). November 7-9, 2022: Washington, DC."},{"key":"e_1_3_3_16_2","unstructured":"ViiV Healthcare. Cabenuva PI. 2021. Available at: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2021\/212888s000lbl.pdf. [Accessed July 30 2025]."},{"key":"e_1_3_3_17_2","unstructured":"Goodrich DE Miake-Lye I Braganza MZ et al. Quality Enhancement Research Initiative. QUERI Roadmap for Implementation and Quality Improvement. United States Department of Veterans Affairs Veterans Health Administration Office of Research and Development Health Services Research and Development. 2020. Available at: https:\/\/www.queri.research.va.gov\/tools\/QUERI-Implementation-Roadmap-Guide.pdf. [Accessed July 30 2025]."},{"key":"e_1_3_3_18_2","doi-asserted-by":"publisher","DOI":"10.1186\/s13012-017-0635-3"},{"key":"e_1_3_3_19_2","unstructured":"ATLAS.ti. ATLAS.ti Scientific Software Development GmbH. ATLAS.ti Mac (version 22) [Qualitative data analysis software]. 2023. Available at: https:\/\/atlasti.com\/. [Accessed July 30 2025]."},{"key":"e_1_3_3_20_2","doi-asserted-by":"publisher","DOI":"10.1186\/1748-5908-4-50"},{"key":"e_1_3_3_21_2","doi-asserted-by":"publisher","DOI":"10.1186\/s13012-022-01245-0"},{"key":"e_1_3_3_22_2","doi-asserted-by":"publisher","DOI":"10.1007\/s10488-010-0319-7"},{"key":"e_1_3_3_23_2","article-title":"Standards for reporting implementation studies (StaRI) statement","volume":"356","author":"Pinnock H","year":"2017","unstructured":"Pinnock H, Barwick M, Carpenter CR, et al. Standards for reporting implementation studies (StaRI) statement. BMJ. 2017;356:i6795.","journal-title":"BMJ."},{"key":"e_1_3_3_24_2","doi-asserted-by":"publisher","DOI":"10.3389\/frph.2023.1201087"},{"key":"e_1_3_3_25_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jana.2016.03.001"},{"key":"e_1_3_3_26_2","doi-asserted-by":"publisher","DOI":"10.1007\/s10461-024-04490-0"},{"key":"e_1_3_3_27_2","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3018(20)30340-4"},{"key":"e_1_3_3_28_2","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciad020"},{"key":"e_1_3_3_29_2","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofae282"}],"container-title":["Journal of the International Association of Providers of AIDS Care (JIAPAC)"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/23259582261439585","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/23259582261439585","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/23259582261439585","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,17]],"date-time":"2026-05-17T12:25:17Z","timestamp":1779020717000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/23259582261439585"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1]]},"references-count":28,"alternative-id":["10.1177\/23259582261439585"],"URL":"https:\/\/doi.org\/10.1177\/23259582261439585","relation":{},"ISSN":["2325-9582","2325-9582"],"issn-type":[{"value":"2325-9582","type":"print"},{"value":"2325-9582","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1]]},"article-number":"23259582261439585"}}